StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC)

StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC - Free Report) in a research report released on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company's stock.

A number of other equities analysts have also recently weighed in on RVNC. Needham & Company LLC restated a "hold" rating on shares of Revance Therapeutics in a report on Friday. William Blair reaffirmed a "market perform" rating on shares of Revance Therapeutics in a research note on Monday, August 12th. Stifel Nicolaus decreased their price objective on shares of Revance Therapeutics from $24.00 to $20.00 and set a "buy" rating for the company in a research report on Friday, August 9th. Guggenheim restated a "neutral" rating on shares of Revance Therapeutics in a research note on Monday, August 12th. Finally, Barclays reissued an "equal weight" rating and issued a $7.00 price target (down previously from $10.00) on shares of Revance Therapeutics in a report on Friday, September 13th. Nine investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $9.66.

Revance Therapeutics Trading Down 36.0 %

Shares of Revance Therapeutics stock traded down $2.08 during trading hours on Friday, reaching $3.70. 13,145,829 shares of the company's stock were exchanged, compared to its average volume of 1,611,994. The firm has a market capitalization of $387.83 million, a price-to-earnings ratio of -1.92 and a beta of 0.95. Revance Therapeutics has a 52-week low of $2.30 and a 52-week high of $9.74. The company has a fifty day moving average of $5.66 and a 200-day moving average of $4.42.

Revance Therapeutics (NASDAQ:RVNC - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.02). The firm had revenue of $59.88 million during the quarter, compared to analyst estimates of $67.73 million. On average, equities research analysts anticipate that Revance Therapeutics will post -1.53 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Revance Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Certuity LLC bought a new stake in Revance Therapeutics in the 2nd quarter valued at about $26,000. Vanguard Personalized Indexing Management LLC bought a new position in Revance Therapeutics in the 2nd quarter worth approximately $33,000. Hsbc Holdings PLC acquired a new stake in Revance Therapeutics in the 2nd quarter valued at approximately $38,000. Nisa Investment Advisors LLC raised its stake in Revance Therapeutics by 2,167.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company's stock valued at $49,000 after acquiring an additional 18,077 shares in the last quarter. Finally, Creative Planning acquired a new position in Revance Therapeutics during the 3rd quarter worth $56,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.